Silver Book Fact

In individuals with persistent low back pain, tanezumab, a humanized anti-nerve growth factor antibody, showed clinical and statistical analgesic efficacy that was superior to placebo and naproxen.

Katz, Nathaniel, David G Borenstein, Charles Birbara, Candace Bramson, Mary Anne Nemeth, Mike D Smith, and Mark T Brown. Efficacy and Safety of Tanezumab in the Treatment of Chronic Low Back Pain. Pain. 2011; 152(10): 2248-58. http://www.painjournalonline.com/article/S0304-3959%2811%2900316-2/abstract

Reference

Title
Efficacy and Safety of Tanezumab in the Treatment of Chronic Low Back Pain
Publication
Pain
Publication Date
2011
Authors
Katz, Nathaniel, David G Borenstein, Charles Birbara, Candace Bramson, Mary Anne Nemeth, Mike D Smith, and Mark T Brown
Volume & Issue
Volume 152, Issue 10
Pages
2248-58
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Nerve growth factor (NGF) has been found to be a major mediator of inflammatory and neuropathic pain and provides a new therapeutic target.  
  • Use of stem cells to create neurons could enable the study of the response of human cells to new drugs in vitro, early in the drug development process.  
  • 57% of American adults say they would pay an extra $1 per week in taxes in order to support government research into the causes of and treatment for chronic pain.  
  • Topical capsaicin was found in a meta-analysis to provide a degree of pain relief to some patients with painful neuropathic conditions.  
  • Targeting A-type K+ channels in primary sensory neurons could provide a novel mechanism-based therapy for the treatment of bone cancer pain–one of the most severe types of chronic pain.